QALYS are higher the longer patients live in good health and the more QALYS, the higher the price of the treatment that NICE will consider acceptable. We have seen that the vast majority of patients who receive DCVax-L will have a life extension of only a few months so that the QALYs will not be that high, whereas life extension is astronomically higher when DVax-L is combined with Poly-iclc and pembrolizumab - median life span > 5yrs - so that the price that NICE will be prepared to accept is that much higher than for DCVax-L on its own. Does anybody know how NICE calculates QALYs in cases such as this?
News 
Market Data 
Discover 
